Atreca to Participate at Cowen’s 43rd Annual Health Care Conference
March 01, 2023 08:00 ET
|
Atreca, Inc.
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
February 06, 2023 08:00 ET
|
Atreca, Inc.
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics...
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
January 09, 2023 08:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
November 10, 2022 16:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused...
Atreca to Present at Upcoming Investor Conferences
November 07, 2022 16:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 05, 2022 16:05 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca to Present at Upcoming Investor Conferences
September 09, 2022 16:05 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 08, 2022 16:05 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca to Present at Upcoming Investor Conferences
August 02, 2022 16:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
June 16, 2022 16:05 ET
|
Atreca, Inc.
SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...